Inhibikase Therapeutics (IKT) Short Interest
Nasdaq • IKT • US45719W2052
As of Oct 27, 2026, ORTEX estimated 24.3% of free float sold short, 29.4 days to cover, cost to borrow 1.06%. Sign up for live short interest data.
Nasdaq • IKT • US45719W2052
As of Oct 27, 2026, ORTEX estimated 24.3% of free float sold short, 29.4 days to cover, cost to borrow 1.06%. Sign up for live short interest data.
This page tracks how heavily Inhibikase Therapeutics (Nasdaq:IKT) is being shorted: ORTEX's daily short interest estimate, the cost to borrow the shares, utilization of the lendable supply and days to cover, next to the official exchange-reported figure.
Source: ORTEX. Some figures are limited on the free view; live data and full history are part of ORTEX Advanced.
Inhibikase Therapeutics (Nasdaq: IKT) has a market capitalization of $326.36M. Last close $1.63 (as of 2026-11-12); 52-week range $1.40 to $2.61. ORTEX data as of 2026-10-27: short interest was 24.34% of free float, 29.4 days to cover and the average cost to borrow was 1.06%. Sign up for live short interest data.